Fainsinger R L, MacEachern T, Miller M J, Bruera E, Spachynski K, Kuehn N, Hanson J
Palliative Care Program, Edmonton General Hospital, Alberta, Canada.
J Pain Symptom Manage. 1994 Jul;9(5):298-302. doi: 10.1016/0885-3924(94)90187-2.
The need to treat dehydration in terminally ill patients to minimize symptom distress remains a controversial issue. Hypodermoclysis (HDC) is a simple technique for rehydration that offers many advantages over the intravenous route. In this prospective open study of 100 consecutive patients who died on a palliative care unit, we recorded our indications for, and use of, HDC. Of the 100 patients, 69 received HDC for an average of 14 +/- 18 days during an average admission of 35 +/- 41 days. The 31 patients who did not receive HDC had an average admission of 22 +/- 24 days, and appeared to have different characteristics than the HDC group. HDC was well tolerated in most patients at an average volume of 1203 +/- 505 mL/day. These results confirm that HDC for dehydration is a safe and effective technique and suggest the need for further research to clarify the role of rehydration in assisting symptom control.
治疗晚期患者的脱水以尽量减轻症状困扰的必要性仍是一个有争议的问题。皮下输液（HDC）是一种简单的补液技术，与静脉途径相比有许多优势。在这项对100例在姑息治疗病房死亡的连续患者进行的前瞻性开放性研究中，我们记录了使用HDC的指征及使用情况。100例患者中，69例接受了HDC，平均住院35±41天期间平均接受HDC治疗14±18天。未接受HDC的31例患者平均住院22±24天，其特征似乎与接受HDC的组不同。大多数患者对HDC耐受性良好，平均输液量为1203±505毫升/天。这些结果证实，HDC治疗脱水是一种安全有效的技术，并表明需要进一步研究以阐明补液在辅助症状控制中的作用。
